---
layout: post
title: "Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK TABLETS, New Drug Application 212725"
date: 2026-02-05 19:00:02 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-16504
original_published: 2022-08-02 00:00:00 +0000
significance: 8.00
---

# Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK TABLETS, New Drug Application 212725

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** August 02, 2022 00:00 UTC
**Document Number:** 2022-16504

## Summary

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ROZLYTREK TABLETS new drug application (NDA) 212725 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/08/02/2022-16504/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rozlytrek-tablets-new)
- API: https://www.federalregister.gov/api/v1/documents/2022-16504

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
